Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the ...
More antibodies take aim at seeded propagation. New data ties tangle location to deficits in specific cognitive domains. Three first-in-human studies for antibodies targeting different parts of tau ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results